Privia Health Group (NASDAQ:PRVA) Director Matthew Shawn Morris Sells 59,037 Shares of Stock

Privia Health Group, Inc. (NASDAQ:PRVA) Director Matthew Shawn Morris sold 59,037 shares of the firm’s stock in a transaction dated Thursday, July 2nd. The shares were sold at an average price of $27.33, for a total value of $1,613,481.21. Following the sale, the director directly owned 76,651 shares in the company, valued at approximately $2,094,871.83. This represents a 43.51% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Matthew Shawn Morris also recently made the following trade(s):

• On Monday, July 6th, Matthew Shawn Morris sold 53,722 shares of Privia Health Group stock. The stock was sold at an average price of $27.24, for a total value of $1,463,387.28.
• On Monday, June 29th, Matthew Shawn Morris sold 63,212 shares of Privia Health Group stock. The stock was sold at an average price of $25.33, for a total value of $1,601,159.96.
• On Friday, June 26th, Matthew Shawn Morris sold 88,110 shares of Privia Health Group stock. The stock was sold at an average price of $25.33, for a total value of $2,231,826.30.
• On Friday, May 1st, Matthew Shawn Morris sold 17,096 shares of Privia Health Group stock. The shares were sold at an average price of $24.99, for a total transaction of $427,229.04.
• On Monday, May 4th, Matthew Shawn Morris sold 1,017 shares of Privia Health Group stock. The shares were sold at an average price of $24.96, for a total transaction of $25,384.32.

Privia Health Group Price Performance

Privia Health Group stock opened at $27.23 on Wednesday. Privia Health Group, Inc. has a 1 year low of $18.77 and a 1 year high of $27.70. The firm’s 50 day moving average price is $23.59 and its 200-day moving average price is $23.06. The stock has a market cap of $3.43 billion, a P/E ratio of 170.20, a PEG ratio of 2.15 and a beta of 0.83.

Institutional Investors Weigh In On Privia Health Group

Several institutional investors have recently made changes to their positions in PRVA. Bayban bought a new position in Privia Health Group during the 4th quarter valued at about $26,000. Hantz Financial Services Inc. grew its stake in shares of Privia Health Group by 456.2% during the fourth quarter. Hantz Financial Services Inc. now owns 1,129 shares of the company’s stock valued at $27,000 after buying an additional 926 shares during the last quarter. Global Retirement Partners LLC grew its stake in shares of Privia Health Group by 579.8% during the fourth quarter. Global Retirement Partners LLC now owns 1,584 shares of the company’s stock valued at $38,000 after buying an additional 1,351 shares during the last quarter. Harbor Investment Advisory LLC purchased a new stake in shares of Privia Health Group in the second quarter worth approximately $69,000. Finally, Canada Pension Plan Investment Board lifted its stake in shares of Privia Health Group by 48.0% during the 2nd quarter. Canada Pension Plan Investment Board now owns 3,700 shares of the company’s stock worth $85,000 after acquiring an additional 1,200 shares during the last quarter. Institutional investors own 94.48% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently commented on PRVA shares. Barclays dropped their price target on Privia Health Group from $25.00 to $24.00 and set an “equal weight” rating for the company in a research note on Tuesday, May 26th. Weiss Ratings raised shares of Privia Health Group from a “hold (c-)” rating to a “hold (c)” rating in a report on Thursday, July 2nd. Canaccord Genuity Group reduced their price target on shares of Privia Health Group from $35.00 to $34.00 and set a “buy” rating on the stock in a research report on Friday, May 8th. Finally, Evercore set a $26.00 price objective on shares of Privia Health Group in a research report on Wednesday, April 8th. Eleven research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Privia Health Group has a consensus rating of “Moderate Buy” and an average target price of $31.15.

About Privia Health Group

Privia Health Group (NASDAQ: PRVA) is a physician enablement company that partners with independent physicians, medical groups and health systems to transform the delivery of patient care. Through a clinically integrated network and a proprietary technology platform, the company supports providers in managing population health, delivering coordinated care and optimizing financial performance under both fee-for-service and value-based reimbursement models.

Founded in 2016 and headquartered in McLean, Virginia, Privia Health has rapidly expanded its footprint to serve multiple metropolitan markets across the United States.